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Background: A few observational studies have found an inverse association between adherence to a
Mediterranean diet and the risk of depression. Randomized trials with an intervention based on this dietary pattern
could provide the most definitive answer to the findings reported by observational studies. The aim of this study
was to compare in a randomized trial the effects of two Mediterranean diets versus a low-fat diet on depression
risk after at least 3 years of intervention.
Methods: This was a multicenter, randomized, primary prevention field trial of cardiovascular disease (Prevención
con Dieta Mediterránea (PREDIMED Study)) based on community-dwelling men aged 55 to 80 years and women
aged 60 to 80 years at high risk of cardiovascular disease (51% of them had type 2 diabetes; DM2) attending
primary care centers affiliated with 11 Spanish teaching hospitals. Primary analyses were performed on an
intention-to-treat basis. Cox regression models were used to assess the relationship between the nutritional
intervention groups and the incidence of depression.
Results: We identified 224 new cases of depression during follow-up. There was an inverse association with
depression for participants assigned to a Mediterranean diet supplemented with nuts (multivariate hazard ratio (HR)
0.78; 95% confidence interval (CI) 0.55 to 1.10) compared with participants assigned to the control group, although
this was not significant. However, when the analysis was restricted to participants with DM2, the magnitude of the
effect of the intervention with the Mediterranean diet supplemented with nuts did reach statistical significance
(multivariate HR = 0.59; 95% CI 0.36 to 0.98).
Conclusions: The result suggest that a Mediterranean diet supplemented with nuts could exert a beneficial effect
on the risk of depression in patients with DM2.
Trial registration: This trial has been registered in the Current Controlled Trials with the number ISRCTN 35739639
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Unipolar depression affects more than 151 million
people worldwide, is a leading cause of years of healthy
life lost as a result of disability (years lost to disability;
YLD) [1], and is projected to be the leading cause of
disability-adjusted life years lost (DALYs) in 2030 [2].
However, little research has been performed on the
modifiable risk factors of unipolar depression that can
provide a means for its effective prevention. Whereas
the role of diet in other chronic conditions with a high
burden of disease such as cardiovascular disease (CVD)
has been extensively studied, the role of diet in the pre-
vention of mental disorders such as depression is an in-
teresting field that has only emerged in the past few
years [3].
Most of the epidemiological studies carried out to date
have analyzed the relationship of individual food groups
and nutrients (such as folic acid or omega-3 fatty acids)
with the risk of depression [4-6]. Only a few epidemio-
logical studies, most of which had a cross-sectional de-
sign, have analyzed the role of overall dietary patterns
on depression risk [7-13]. A healthy dietary pattern such
as the Mediterranean diet (hereafter referred to as MD)
was uniquely associated with a lower risk of depression
or depressive symptoms in two observational prospective
studies [14,15].
However, one of the most important limitations in ob-
servational epidemiology is to obtain adequate control of
confounding. This is a key methodological issue because
potential effects of dietary patterns on depression could
be explained in part by the co-occurrence of other
lifestyle-related and sociodemographic factors, or by
medical conditions closely related to the adherence to a
particular dietary pattern.
This issue could be solved by carrying out large ran-
domized primary prevention trials with interventions
based on changes in the overall food pattern. The
PREDIMED (Prevención con Dieta Mediterránea) trial
was a nutritional intervention study designed to assess
the role of the MD in the primary prevention of CVD
[16], and provided an ideal setting to investigate the ef-
fect of the MD on the risk of developing depression.
Thus the aim of this analysis was to assess the effects of
two Mediterranean diets (MD supplemented with extra
virgin olive oil (MD-EVOO), and MD supplemented
with mixed nuts (MD-nuts)) on depression risk, in com-
parison with a low-fat control diet.
Methods
Study population
This study was conducted within the frame of the
PREDIMED trial. The design of the PREDIMED trial has
been reported in detail elsewhere [17]. Briefly, the
PREDIMED trial was a large, parallel-group, multicenter,randomized controlled clinical trial that aimed to assess
the effects of a Mediterranean-type diet on CVD. The
study population was composed of men aged between
55 and 80 years and women aged between 60 and 80
years with no previously documented CVD, but who
were at high cardiovascular risk. Inclusion criteria were
either diabetes mellitus type 2 (DM2) or at least three of
the following cardiovascular risk factors: current smo-
king, hypertension (HTA), low-density lipoprotein (LDL)
cholesterol >4.110 mmol/l, high-density lipoprotein (HDL)
cholesterol <1.034 mmol/l, overweight/obesity, or a family
history of premature coronary heart disease.
Recruitment of participants took place in primary care
centers affiliated with 11 Spanish teaching hospitals be-
tween October 2003 and June 2009. In total, 7,447 par-
ticipants were recruited. Of these 1,618 subjects who
reported prevalent depression, previous history of de-
pression, or use of antidepressant drugs at baseline were
excluded. Participants with a follow-up of less than 3
years (n=1,870) were also excluded in order to minimize
the influence of possible reverse causation from the
presence of undiagnosed disease at baseline, as were
those with missing data for several covariates (n=33),
and those with dementia (n=3). Thus, the final sub-
sample consisted of 3,923 participants (Figure 1).Ethics
All participants provided written informed consent, and
the protocol was approved by the institutional review
boards of the participating centers, in accordance with
the Declaration of Helsinki.The institutional review
board of the Hospital Clínic (Barcelona, Spain), which is
accredited by the Department of Health and Human
Services and regulated by the Federal wide Assurance
for the Protection of Human Subjects of International
(Non-US) Institutions (number 00000738), approved
the study protocol on July 16, 2002. This trial was
registered with the Current Controlled Trials (number
ISRCTN 35739639).Study interventions
Participants were randomly assigned, in a 1:1:1 ratio, to
one of the three PREDIMED dietary interventions: the
low-fat diet (control group), the MD-+EVOO, and the
MD-+nuts by a nurse at each center. The study nurses
were independent of the nurse staff of the primary care
center, and therefore, were not involved in the usual
clinical care of participants, their primary and exclusive
role was to collect the data for the PREDIMED trial.
Randomization was performed centrally by means of a
computer-generated random-number sequence. The pri-
mary care physicians did not participate in the process
of randomization.
Figure 1 Profile of the PREDIMED (Prevención con Dieta Mediterránea) field trial.
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cation to follow the MD and supplemental foods at no
cost. EVOO (1 l/week) was provided to the MD-EVOO
group, and 30 g/day of mixed nuts (15 g walnuts, 7.5 g
hazelnuts and 7.5 g almonds) to the MD-nuts group.
The control group did not receive education on the MD,
but was instead given advice to follow a low-fat diet,
including recommendations to reduce all types of fat in-
take, from both animal and vegetable sources, in accord-
ance with American Heart Association guidelines [18].
To encourage adherence, small non-food gifts, such as
kitchenware, tableware, aprons, or shopping bags, were
given. Energy restriction was not advised and physical
activity was not promoted for any of the groups.
A behavioral intervention promoting the MD was
implemented in both MD groups, as described previ-
ously [16,19]. In brief, an initial assessment of individual
scores of adherence was carried out using a validated
14-item questionnaire [20], and based on this, 25 dieti-
tians gave personalized dietary advice to participantsrandomly assigned to either of the MD groups, with the
aim of improving participants’ scores on the question-
naire. Recommendations included, among others: 1)
abundant use of olive oil for cooking and dressing; 2)
increased consumption of fruit, vegetables, legumes,
and fish; 3) reduction in total meat consumption,
recommending white meat instead of red or processed
meat; 4) preparation of homemade sauce with tomato,
garlic, onion, and spices with olive oil to dress vegeta-
bles, pasta, rice, and other dishes; 5) avoidance of butter,
cream, fast food, sweets, pastries, and sugar-sweetened
beverages; and 6) (for alcohol drinkers) moderate con-
sumption of red wine.
At baseline and every 3 months, dietitians conducted
both individual interviews and group sessions with a
maximum of 20 participants, separately for each group.
Sessions consisted of informative talks and delivery of
written material with detailed descriptions of typical
foods for each dietary pattern, seasonal shopping lists,
meal plans, and recipes.
Sánchez-Villegas et al. BMC Medicine 2013, 11:208 Page 4 of 11
http://www.biomedcentral.com/1741-7015/11/208Outcome
An incident case of depression was defined as a diagno-
sis of depression made by a physician and reported by
participants in any of the follow-up interviews, or a po-
sitive report of habitual use of antidepressant drugs.
Only outcomes occurrring between October 1, 2006,
and December 1, 2010, were included in the analyses.
Covariates
At baseline and at follow-up once yearly, a validated
semi-quantitative 137-item food frequency questionnaire
[21,22] was administered by trained dietitians to deter-
mine energy and nutrient intake, using Spanish food
composition tables [23]. Alcohol intake was also ascer-
tained through use of this questionnaire.
Physical activity was measured at the baseline visit and
at follow-up every year using the validated Spanish ver-
sion of the Minnesota Leisure Time Physical Activity
Questionnaire [24]. Other lifestyle-related variables such
as smoking, health conditions (for example, prevalence
of any one of a number of chronic diseases), and socio-
demographic variables (for example, sex, age, educa-
tional level, marital status) were assessed by a general
questionnaire based on 47 items, as described in detail
previously [16,17]. In addition, anthropometric variables
such as height and weight were also measured. Body
mass index (BMI) was defined as weight (in kilograms)
divided by the height (in meters) squared.
Statistical analysis
Primary analyses were performed on an intention-to-treat
(ITT) basis. Cox regression models were used to assess the
relationship between the nutritional intervention groups
and the incidence of depression. Hazard ratios (HR) and
95% confidence interval (95% CI) were calculated using the
control group as the reference category. Participants con-
tributed to the follow-up period up to the date of death,
diagnosis of depression, or December 1, 2010, whichever
came first. Potential confounders included as covariates in
the multiple-adjusted Cox regression models were: age, sex,
recruiting center (11 centers), BMI (normal, overweight,
obese), smoking (never-smoker, current smoker, and ex-
smoker), physical activity during leisure time (quartiles),
educational level (primary, secondary, or university), marital
status (married, others), alcohol intake (g/day), and total en-
ergy intake (kcal/day) and prevalence of various chronic
diseases (cancer, DM2, HTA, hypercholesterolemia, frac-
tures, Parkinson disease (PD), and chronic bronchitis) at
baseline.
Several sensitivity analyses were conducted by alterna-
tive Cox regression analyses after 1) excluding late cases
of depression (after 6 years of follow-up); 2) including only
participants with DM2, HTA, or hypercholesterolemia; 3)
excluding those participants with a history of limitingdiseases (fractures, PD, and chronic bronchitis) or cancer;
and 4) excluding those centers with lower retention rate.
In addition, in the sensitivity analyses those partici-
pants whom the PREDIMED team had not been able to
contact for at least 2 years and who did not have a diag-
nosis of incident depression were considered as partici-
pants with a missing value for the outcome. In such
cases, the analyses were also repeated after multiple im-
putation for these missing data [25].
Finally, in addition to the previous ITT analysis, the
analyses were also repeated using a per-protocol analysis
[26]. After 3 years of follow-up, participants completed
the 14-item MD adherence questionnaire [20]. Three
categories of adherence after 3-year follow-up were cre-
ated: high (≥10 points in the score); medium
(8 to 9 points) and low (<8 points) adherence to the
MD. Those participants with a 3-year Mediterranean
score of less than 8 points were considered as the refer-
ence category in the Cox regression models. The results
were adjusted for age, sex, intervention group, recruiting
center, smoking, educational level, marital status, and
prevalence of various chronic diseases at baseline, plus
BMI, alcohol intake (except wine - this item was included
in the 14-item MD adherence questionnaire), energy in-
take, and physical activity after 3 years of follow-up.
All P-values were two-tailed, and P<0.05 was consid-
ered significant. Analyses were performed using the soft-
ware programs SPSS (version 19; SPSS Inc., Chicago, IL,
USA) and STATA (version 12.1; StataCorpLP, College
Station, TX, USA).
Results
The main characteristics of the participants in each nu-
tritional intervention group are presented in Table 1.
The groups were well balanced with respect to most
relevant variables. Participants in the control group were
less physically active and had a lower alcohol intake, and
the percentages both of married subjects and of parti-
cipants with a higher educational level (university) were
lower.
We identified 224 new cases of depression during the
follow-up period (median 5.4 years). The effect of the in-
terventions on the incidence of depression is shown in
Table 2. An inverse association with depression was seen
for participants assigned to receive MD-nuts, although
this was not significant; multivariate HR = 0.78 (95% CI
0.55 t. 1.10) for the MD-nuts group compared with the
control (low-fat) group. When both MDs were merged
together and analyzed as a single group, no significant
association was found between the MD intervention and
depression risk (multivariate HR = 0.85; 95% CI 0.64 to
1.13).
Results from sensitivity analyses are shown in Table 3.
In most of the sub-analyses, similar results to those
Table 1 Characteristics of participants in each
randomized intervention group
MD-EVOO MD-nuts Control diet
(n=1446) (n=1293) (n=1184)
Age, years 67.1, 6.2 66.7, 6.0 67.4 (6.4)
Male sex, % 47.1 53.5 46.2
Smoking status, %
Never-smoker 57.7 56.5 58.1
Current smoker 14.5 15.2 14.9
Marital status, %
Married 80.2 79.9 77.0
Educational level, %
Primary or lower 76.5 75.2 79.1
University 8.6 8.4 6.3
Disease prevalence, %
Cancer 2.1 3.2 2.3
Diabetes 52.4 48.1 50.7
Hypertension 80.2 81.1 82.3
Hypercholesterolemia 68.9 69.5 67.7
Parkinson disease 0.3 0.3 0.3
Chronic bronchitis 4.8 4.7 5.4
Fractures 16.1 17.8 18.7
Body mass index, kg/m2 29.8, 3.7 29.6, 3.7 30.1 (4.0)
Total energy intake,
kcal/day
2317.9, 619.1 2384.1, 611.0 2256.4 (605.8)
Alcohol intake, g/day 10.0, 15.6 11.2, 17.1 9.0 (14.9)
Physical activity during
leisure time, METs-min/day
247.4, 243.6 270.9, 258.7 226.9 (261.1)
Abbreviations: MET metabolic equivalent, EVOO extra virgin olive oil.
Table 2 Risk of incident depression in each randomized
group
Nutritional intervention
Control diet MD-EVOO MD-nuts
Cases 77 88 59
Person-years 6,096 7,715 6,803
Model 1a
HR (95% CI) 1 (ref) 0.85 (0.62 to 1.15) 0.73 (0.52-1.03)
HR (95% CI)b 1 (ref) 0.80 (0.60 to 1.05)
Model 2c
HR (95% CI) 1 (ref) 0.91 (0.67 to 1.24) 0.78 (0.55-1.10)
HR (95% CI)b 1 (ref) 0.85 (0.64 to 1.13)c
Abbreviations: HR hazard ratio, MD Mediterranean diet, ref reference group,
EVOO extra virgin olive oil.
aModel 1: adjusted for age, sex, and recruiting center.
bCombined MD.
cModel 2: model 1 additionally adjusted for body mass index, smoking,
physical activity during leisure time, educational level, marital status, alcohol
and total energy intake, and presence of any of several diseases at baseline
(cancer, diabetes mellitus type 2, hypertension, hypercholesterolemia,
fractures, Parkinson disease and chronic bronchitis).
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tions of around 20 to 30% in the risk of developing de-
pression for those participants assigned to the MD-nuts
intervention, although the estimates did not reach sta-
tistical significance. However, when the analysis was
restricted to participants with DM2, a stronger and sig-
nificant reduction in the risk of depression was seen for
participants assigned to the MD-nuts group compared
with those assigned to the control group (41% relative
reduction in the risk of developing depression; 95% CI
0.36 to 0.98; P = 0.04).
Table 4 shows the results from the per-protocol ana-
lysis. After 3 years of follow-up, we had complete data
from 2,513 participants about their dietary habits and
energy intake. Compared to those participants with the
lowest adherence to the MD, those with the highest ad-
herence to the MD did not show a significant decrease
in the risk of developing depression during the follow-
up (multivariate HR = 0.71; 95% CI 0.38 to 1.32).
Discussion
We did not find a significant decrease in depression risk
among participants at high risk of CVD assigned to MD
supplemented with either nuts or EVOO in this ran-
domized controlled primary prevention trial. However,
when the analysis was restricted to subjects with DM2,
participants assigned to MD-nuts had a 40% reduction
in depression risk compared with the control group,
which was significant.
To our knowledge, this is the first randomized field
trial that has ascertained the effect of an intervention
with an overall dietary pattern on depression risk in
adults. Only a few prospective observational studies have
inversely related healthy dietary patterns to the risk of
developing adult depression [7-15]. Although some of
these studies were based only on cross-sectional as-
sessments [8,9,11-13], their results were consistent
with those obtained after several years of follow-up in
prospective cohorts [7,10].
Regarding the MD, a very recent cohort study, the
Australian Longitudinal Study on Women’s Health [14],
found that women in the highest quintile of adherence
to a ‘Mediterranean-style’ diet were 37% less likely to
report depressive symptoms after 3 years of follow-up,
(adjusted odds ratio (OR) = 0.63, 95% CI 0.47 to 0.85)
compared with those in the lowest quintile of adherence.
Similar results were previously obtained in the SUN
(Seguimiento Universidad de Navarra) Project [15] in
which participants with the highest adherence to the
MD had a significant reduction in the risk of developing
depression (comparison of fifth versus first quintile: ad-
justed HR = 0.58; 95% CI 0.44 to 0.77).
Nevertheless, the available evidence is still sparse
and not definitive. Moreover, interpretation of findings
Table 3 Association between nutritional interventions and depressiona
Analysis Total, n Cases, n Nutritional intervention, HR (95% CI)
Control diet MD-EVOO MD-nuts
Excluding late cases (>6 years of follow-up) 3,893 211 1 (ref) 0.88 (0.64 to 1.21) 0.73 (0.52 to 1.05)
Including only participants with diabetes 1,958 113 1 (ref) 0.71 (0.46 to 1.09) 0.59 (0.36 to 0.98)
Including only participants with hypertension 3,181 181 1 (ref) 0.93 (0.66 to 1.31) 0.79 (0.54 to 1.16)
Including only participants with hypercholesterolemia 2,697 158 1 (ref) 0.93 (0.64 to 1.35) 0.81 (0.54 to 1.21)
Including only participants with obesity 1,781 113 1 (ref) 0.85 (0.55 to 1.31) 0.69 (0.41 to 1.13)
Excluding participants with limiting conditionsb 3,074 184 1 (ref) 0.81 (0.57 to 1.13) 0.68 (0.46 to 0.99)
Excluding participants with cancer 3,824 216 1 (ref) 0.90 (0.66 to 1.24) 0.79 (0.56 to 1.12)
Excluding participants with potentially missing eventsc 3,867 224 1 (ref) 0.91 (0.66 to 1.24) 0.78 (0.55 to 1.10)
Multiple imputation for missing values 82,383 4,740 1 (ref) 0.95 (0.69 to 1.32) 0.75 (0.52 to 1.07)
Abbreviations: HR hazard ratio, MD Mediterranean diet, ref reference group, EVOO extra virgin olive oil.
aAdjusted for age, sex, recruiting center, body mass index, smoking, physical activity during leisure time, educational level, marital status, alcohol and total energy
intake, and the presence of several diseases at baseline (cancer, diabetes mellitus type 2, hypertension, hypercholesterolemia, fractures, Parkinson disease and
chronic bronchitis).
bSuch as fractures, PD, and chronic bronchitis.
cApproaches for dealing with missing data were as follows. We implemented the suggestions given by Groenwold et al. [25] to handle potentially missing
outcome data in randomized trials. In order to conduct sensitivity analyses on missing outcomes, we considered as missing outcome data the potential
occurrence of depression for 59 participants for whom we had no documented incident depression and who were lost to follow-up for 2 years or longer. We
conducted two sensitivity analyses: 1) in the complete case analysis we excluded these 59 subjects from the computation of HRs and adjusted the Cox model for
all the covariates mentioned in Table 3; 2) in multiple imputations, 20 values were sampled from an estimated uniform distribution (also taking into account the
previously mentioned predictors) and imputed for the 59 participants lost to follow-up adding a random term. Hence, 20 datasets with imputed outcomes were
created. Each dataset was analyzed using multivariable-adjusted Cox models and, subsequently, the results were pooled by using standard techniques, also taking
into account the variation between imputed data sets [24].
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[3]. Most of the studies had a cross-sectional design
[8,9,11-13], which is a weak design for inferring cause and
effect relationships that can only be suggested. In such
studies, exposure is ascertained simultaneously with dis-
ease and, therefore, an alternative interpretation of the re-
sults could be made as a consequence of reverse causation
bias; for example, that depression may lead to poorer diet-
ary habits [27]. These large studies generally need the use
of food frequency questionnaires to collect information on
dietary factors, and although such questionnaires have
been customarily used and generally have been vali-
dated, it is known that they have some potential forTable 4 Risk of developing depression stratified by level of a
after 3 years of follow-up
Low: <8 points Medium: 8–9
Median (points) 7 9
Cases, n 14 32
Person-years 1,105 3,059
Model 1
HR (95% CI) 1 (ref) 0.81 (0.43 to
Model 2
HR (95% CI) 1 (ref) 0.73 (0.38 to
Abbreviations: HR hazard ratio, MD Mediterranean diet, ref reference.
Model 1: adjusted for age, sex, and recruiting center.
Model 2: model 1 additionally adjusted for intervention group, for smoking, educat
baseline, and body mass index, physical activity during leisure time, alcohol intakemisclassification bias. Finally, it is necessary to take
into account the possibility of residual confounding.
By contrast, findings from observational studies can be
supported by some biochemical and physiological mech-
anisms that may be implicated in depression risk and
that are also intimately related to dietary factors. Exa-
mples include low-grade systemic inflammation and
endothelial and metabolic disturbances, which may be
present in patients with depression [28-31]. Indeed, a
large number of clinical trials including the PREDIMED
study and some observational studies have reported an
inverse association between adherence to a MedDiet
pattern and the levels of inflammatory, metabolic, ordherence to Mediterranean diet (per-protocol analysis)
Adherence to MD




1.51) 0.72 (0.40 to 1.28) 0.26
1.39) 0.71 (0.38 to 1.32) 0.38
ional level, marital status, and the presence of any of several diseases at
(except wine), and total energy intake after 3 years of follow-up.
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matory processes and endothelial dysfunction com-
promise the production and secretion of brain-derived
neurotrophic factor (BDNF), a peptide implicated in syn-
aptic plasticity and neuronal survival, and whose levels
are decreased in patients with depression [36]. In a pre-
vious sub-analysis of the PREDIMED trial, conducted by
our group in the PREDIMED-NAVARRA center, signifi-
cantly higher plasma BDNF levels were seen for patients
with depression assigned to the MD-nuts compared with
those assigned to a control diet [37].
Our results indicate that adherence to a Mediterra-
nean dietary pattern supplemented with nuts could be
particularly important to prevent depression among par-
ticipants with DM2. The association between obesity,
DM2, metabolic syndrome (MetS), and depression has
been suggested in several studies [38-40]. Metabolic dis-
turbances/dysregulation of markers such as insulin, lep-
tin, glucose [30,31], or tryptophan/serotonin [41,42]
could explain the link between obesity, DM2, and de-
pression. In fact, in the Whitehall II cohort study, low
insulin secretion was associated with an increased risk of
developing depressive symptoms [30]. Recent studies
have also reported an increased risk of depressive symp-
toms associated with higher levels of leptin [43], espe-
cially in the presence of abdominal obesity [31,44]. The
association of leptin with depression could be explained
not only by its metabolic properties but also by its
neurobiological activity, as leptin is able to affect neu-
roprotection, cognition, and mood in the hippocampus,
the cortex, and other brain areas [45]. Moreover, in sev-
eral studies, hyperleptinemia and insulin resistance,
which can be present in obesity, MetS, and DM2 have
been also linked to endothelial dysfunction or inflam-
mation processes [46,47], conditions also present in
depression. Not only metabolic disturbances but also in-
flammatory markers have been recently associated with
depressive symptoms in participants with diabetes from
the SEARCH for Diabetes in Youth cohort study [48].
Interestingly, within the PREDIMED trial, several sub-
analyses support this hypothesis. After 3 months of
follow-up, participants assigned to the MD+ nuts
exhibited significant reductions in fasting glucose and in-
sulin levels and in Homeostasis Model Assessment index
compared to those assigned to the control diet [49]. More-
over, a significant reversion of MetS was seen in the MD-
nuts group after 1 year of intervention; in this group, the
OR for reversion of MetS was 1.7 (95% CI=1.1 to 2.6)
compared with the control diet group [33].
Moreover, in a recent clinical trial based on a sample
of patients with MetS assigned to receive a control diet
or a diet enriched in mixed nuts for 12 weeks, two inter-
mediate urinary metabolites of the tryptophan pathway
(which leads to biosynthesis of serotonin and melatoninfrom tryptophan) were identified: N-acetylserotonin sul-
fate and hydroxyindoleacetic acid [50]. These metabo-
lites are considered urinary markers of nut intake, as
walnuts are one of the most important dietary sources of
serotonin [51]. However, the authors pointed out that
the presence of these urinary metabolites could be due
both to a high intake of walnuts and to a high endogen-
ous serotonin turnover following the intake of these food
items. Thus, such metabolites could be markers of the
effect of the global dietary intervention, instead of being
markers of intake [50].
We did not find a significant effect on depression risk
for adherence to the MD supplemented with EVOO in
the overall sample. However, when the analyses were re-
stricted to those participants with DM2. the relationship
was strengthened. The effect on depression of the inter-
vention with MD supplemented with EVOO for patients
with DM2, although non-significant, was similar to that
obtained for patients with DM2 in the analysis of the ef-
fect of MD on risk of CVD in the PREDIMED frame-
work [16]. As mentioned above, several physiological
processes may be responsible for the link between de-
pression and cardiovascular and metabolic disorders
[28-31]. In fact, a beneficial role of supplementation with
a Mediterranean diet enriched with olive oil in various
processes such as oxidative stress, inflammation, lipid
metabolism, or weight regulation for patients with DM2
or multiple sclerosis has been described in several epi-
demiological studies [52-54].
Although our results indicate a possible beneficial role
of MD supplemented with nuts (compared with a low-
fat diet) in the prevention of depression, with a risk re-
duction of around 25%, the results were not statistically
significant. There are several reasons that may explain
the lack of statistical significance. First, the number of
new cases was not large. In the report from the SUN
cohort relating the Mediterranean diet with depres-
sion, 480 new cases of depression were identified [15],
whereas in the present study, the number of new cases
was less than half of that the SUN cohort. Second, ob-
servational studies generally compare extreme quintiles
or quartiles of adherence to a dietary pattern, therefore,
high between-subject variability in adherence allows for
comparison of extremes in exposure and guarantees that
a strong effect can be detected. By contrast, in the
present study, the variability in adherence to the MD
between the Mediterranean and control groups was rela-
tively small. In fact, after 6 years of follow-up, the partic-
ipants assigned to the control group showed a mean
adherence to the MD of 9 points (up to 14 points
maximum), whereas the mean adherence within the
groups assigned to both MDs was 10.5 points [16].
Moreover, in intervention trials, the degree of change
in the dietary habits of participants is always suboptimal,
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intervention of some participants [19]. In fact, the con-
trol group in the PREDIMED trial was assigned a
healthy dietary pattern recommended by the American
Heart Association to prevent CVD [18], and also they
tended at baseline to be on a dietary pattern that was
similar to the Mediterranean diet. This reality suggests
that there would be even a potentially greater benefit of
the Mediterranean diet if it were compared to a typical
(and unhealthy) Western diet [16]. Third, the
PREDIMED trial was not designed to study depression
as a primary end-point; the primary end-point was in
fact a composite of cardiovascular clinical events. There-
fore, it is likely that some degree of misclassification in
the ascertainment of depression cases may have hap-
pened. However, we took care to ensure that all included
cases had received a medical diagnosis of depression (or
were under antidepressant treatment), and that they
were not prevalent cases at baseline. In fact, we excluded
all participants with a short follow-up period (the first 3
years) in order to ensure that reverse causation could
not explain the reported results.
Although in the PREDIMED trial, follow-up data were
available for 97% of the sample, it is important to note
that the time each participant remained in the trial was
variable because centers started to recruit participants
from 2004 to 2006, many centers continued to recruit
participants until 2009, and the trial ended in 2010.
Thus, to obtain a more homogeneous period of follow-
up in all participants, we carried out our analyses only
with those participants with at least 3 years of follow-up.
Usually, to minimize the influence of the presence of un-
diagnosed disease at baseline, a methodological approach
in cohort studies has been to exclude cases occurring
during the first 3 [55] or even the first 5 years of follow-
up [56]. We chose a 3-year period because we believed it
likely that participants with undetected (sub-clinical) de-
pression at baseline might receive a delayed diagnosis of
depression during the first, second, or even third year of
follow-up. However, we considered that in participants
with true but undiagnosed depression at baseline, it was
unlikely that their depression would remain undetected
during the first 3 years of follow-up and that they might
yet receive a delayed diagnosis only during the fourth
year of follow-up or later.
One of the main problems of a nutritional intervention
trial is the variability in the compliance of participants
with the intended dietary intervention. To address this
issue, we carried out a per protocol approach as an an-
cillary analysis to compare the results, taking into ac-
count what the participants really did. The category of
highest adherence to the MD after 3 years of interven-
tion exhibited the lowest risk of depression. This is con-
sistent with the results obtained in the ITT analyses.However, in both case,s the lack of statistical significance
is probably attributable to the small number of cases
included.
Finally, the highest retention rates were seen in the
MD groups, and the lowest retention rate was seen in
the control (low-fat diet) group. This high retention rate
in the two MD group by be partly attributable to the free
provision of specific food items (EVOO and nuts). In
additon, the palatability of the Mediterranean diet has
been identified as a key factor in its higher compliance
[57]. In general, the research group was able to obtain
nearly complete follow-up for the main outcomes be-
cause participants represented a stable and well-defined
population regularly attending their general practitio-
ners. In addition, a comprehensive search for events was
performed yearly through review of all the medical re-
cords of participants in all the university hospitals of the
area in which the respective recruiting center was lo-
cated. Nevertheless, 59 participants without a diagnosis
of incident depression could not be contacted for at least
2 years (22 participants assigned to the low-fat group, 19
to the MD-nuts and 18 to the MD+EVOO). Thus, differ-
ential misclassification bias in the outcome is not a very
likely possibility. Moreover, when the analyses were re-
peated imputing the missing values for subjects lost to
follow-up, the results did not change substantially.
Conclusions
In conclusion, results from this analysis are suggestive of
a beneficial effect of a long-term intervention with a
Mediterranean diet on depression for patients with
DM2. Nevertheless, to definitely assess the role of Medi-
terranean diet in the prevention of depression, longer
follow-up of this trial and further experimental investi-
gations are needed.
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